Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma.
Keane C, Gould C, Jones K, Hamm D, Talaulikar D, Ellis J, Vari F, Birch S, Han E, Wood P, Le-Cao KA, Green MR, Crooks P, Jain S, Tobin J, Steptoe RJ, Gandhi MK. Keane C, et al. Among authors: gandhi mk. Clin Cancer Res. 2017 Apr 1;23(7):1820-1828. doi: 10.1158/1078-0432.CCR-16-1576. Epub 2016 Sep 20. Clin Cancer Res. 2017. PMID: 27649554
Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphoma.
Cui Q, Vari F, Cristino AS, Salomon C, Rice GE, Sabdia MB, Guanzon D, Palma C, Mathew M, Talaulikar D, Jain S, Han E, Hertzberg MS, Gould C, Crooks P, Thillaiyampalam G, Keane C, Gandhi MK. Cui Q, et al. Among authors: gandhi mk. Oncotarget. 2018 Oct 5;9(78):34644-34657. doi: 10.18632/oncotarget.26141. eCollection 2018 Oct 5. Oncotarget. 2018. PMID: 30410665 Free PMC article.
The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.
Keane C, Tobin J, Gunawardana J, Francis S, Gifford G, Gabrielli S, Gill A, Stevenson W, Talaulikar D, Gould C, Jain S, Birch S, Hertzberg M, Gandhi MK. Keane C, et al. Among authors: gandhi mk. Eur J Haematol. 2019 Sep;103(3):200-207. doi: 10.1111/ejh.13274. Epub 2019 Jul 24. Eur J Haematol. 2019. PMID: 31211907 Free PMC article.
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
Barraclough A, Alzahrani M, Ettrup MS, Bishton M, van Vliet C, Farinha P, Gould C, Birch S, Sehn LH, Sovani V, Ward MS, Augustson B, Biccler J, Connors JM, Scott DW, Gandhi MK, Savage KJ, El-Galaly T, Villa D, Cheah CY. Barraclough A, et al. Among authors: gandhi mk. Blood Adv. 2019 Jul 9;3(13):2013-2021. doi: 10.1182/bloodadvances.2019000251. Blood Adv. 2019. PMID: 31285189 Free PMC article.
Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.
Tobin JWD, Keane C, Gunawardana J, Mollee P, Birch S, Hoang T, Lee J, Li L, Huang L, Murigneux V, Fink JL, Matigian N, Vari F, Francis S, Kridel R, Weigert O, Haebe S, Jurinovic V, Klapper W, Steidl C, Sehn LH, Law SC, Wykes MN, Gandhi MK. Tobin JWD, et al. Among authors: gandhi mk. J Clin Oncol. 2019 Dec 1;37(34):3300-3309. doi: 10.1200/JCO.18.02365. Epub 2019 Aug 28. J Clin Oncol. 2019. PMID: 31461379 Free PMC article.
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.
Tobin JWD, Rule G, Colvin K, Calvente L, Hodgson D, Bell S, Dunduru C, Gallo J, Tsang ES, Tan X, Wong J, Pearce J, Campbell R, Tneh S, Shorten S, Ng M, Cochrane T, Tam CS, Abro E, Hawkes E, Hodges G, Kansara R, Talaulikar D, Gilbertson M, Johnston AM, Savage KJ, Villa D, Morris K, Ratnasingam S, Janowski W, Kridel R, Cheah CY, MacManus M, Matigian N, Mollee P, Gandhi MK, Hapgood G. Tobin JWD, et al. Among authors: gandhi mk. Blood Adv. 2019 Oct 8;3(19):2804-2811. doi: 10.1182/bloodadvances.2019000458. Blood Adv. 2019. PMID: 31570492 Free PMC article.
133 results